Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2017 call → NO我们只需要根据提供的文本判断管理层的描述是否传达了“同类业务连续接单规模逐步扩大”的现象。文本中,管理层提到了一些增长,但需要仔细分析。 关键点: - 管理层提到“unfunded pipeline of mandates is now $903 million up from $317 million in the first quarter”,这表示待执行授权管道从3.17亿增加到9.03亿,但这是管道,不是已签署的订单,且是总量增加,不是单个规模。 - 提到“RFP activity is diverse and running substantially ahead”,但未明确单个规模。 - 提到“we are for the first time enjoying a surge in institutional demand for preferred securities strategies”,但未说单个规模。 - 提到“our relatively new low duration preferred fund were $193 million in the quarter, bringing its total assets to nearly $500 million”,这是基金资产增长,不是单个订单。 - 提到“two new model delivery sub advisory mandates... have begun to fund”,但未说规模。 - 提到“we gained regulatory approval for our global preferred SICAV, which also received funding of $45 million from a Japanese institutional investor”,这是单个投资,但未说比过去大。 - 没有明确说“现在接到的单个合同比过去大”或类似表述。 管理层主要谈论的是整体流量、管道增长、新策略等,但没有明确对比单个业务单元的规模与过去相比是否增大。管道增长可能是数量增加,也可能是规模增加,但未明确。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.